Journal
ORPHANET JOURNAL OF RARE DISEASES
Volume 18, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s13023-023-02671-z
Keywords
Cystic fibrosis; Breast cancer; Estrogens; Anticancer treatment; CFTR modulator therapy
Ask authors/readers for more resources
Cystic fibrosis (CF), the most common genetic disease in the Caucasion population, can be significantly improved by CFTR modulators therapy. Recent epidemiological studies indicate that the increasing incidence of tumors, including breast cancer, poses new therapeutic challenges for CF patients. Chemotherapy used for breast cancer can affect the CFTR channel and CFTR modulator therapy has frequent side effects on breast tissue.
Cystic fibrosis (CF) is the most common genetic disease in the Caucasion population. Thanks to the CFTR modulators therapy, life expectancy will significantly improve. New therapeutic challenges can be expected, including diseases associated with ageing and higher incidence of cancer, as evidenced by recent epidemiological studies. The increasing incidence of tumors includes also breast cancer. The risk of breast cancer is higher in CF patients compared to the general population. Sex hormones, especially estrogens, also affect on the pathophysiology and immunology of the CF. Previous research, has demonstrated unequivocal survival rates for female CF patients compared to their male counterparts. Is demonstrated, that chemotherapy used for breast cancer affects the CFTR channel and CFTR modulator therapy has frequent side effects on breast tissue. In this review, we focus on the effects of female sex hormones on CF disease, pathophysiological relationships between CF and breast cancer, and the impact of antitumor treatment on both, malignant disease and CF. The potential for further investigation is also discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available